Sugi Predict

Sugi Predict / Compounds / SCHEMBL70060

SCHEMBL70060

SCHEMBL70060

C[C](C)CN1CCOCC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.54
▸ HSD17B10 Q99714 3/20 0.54
▸ TSHR P16473 2/20 0.52
▸ ALOX15 P16050 2/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ USP2 O75604 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPT P10636 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ ANPEP P15144 1/20 0.41
▸ GLA P06280 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ KEAP1 Q14145 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28030589 0.85 — —
SCHEMBL12247553 0.82 KDM4E (0.52) KDM4EHSD17B10TSHRALOX15SMN1; SMN2
SCHEMBL12247555 0.82 KDM4E (0.52) KDM4EHSD17B10TSHRALOX15SMN1; SMN2
SCHEMBL27339631 0.82 HSD17B10 (0.58) KDM4EHSD17B10TSHRALOX15SMN1; SMN2
SCHEMBL778962 0.80 KDM4E (0.61) KDM4EHSD17B10TSHRALOX15SMN1; SMN2
SCHEMBL16997012 0.80 KDM4E (0.50) KDM4EHSD17B10TSHRALOX15SMN1; SMN2
SCHEMBL13909062 0.80 KDM4E (0.50) KDM4EHSD17B10TSHRALOX15SMN1; SMN2
SCHEMBL10246598 0.80 KDM4E (0.50) KDM4EHSD17B10TSHRALOX15SMN1; SMN2
SCHEMBL28065682 0.80 KDM4E (0.50) KDM4EHSD17B10TSHRALOX15SMN1; SMN2
SCHEMBL28214812 0.80 KDM4E (0.38) KDM4EHSD17B10TSHRALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298011-B1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2021-11-17 — — EP claimed
US-10154995-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-12-18 — — US claimed
EP-3089788-B1 SERINE/THREONINE KINASE INHIBITORS GENENTECH INC (US) 2018-10-24 — — EP claimed
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 — — EP claimed
US-20180155340-A1 QUINOLONE DERIVATIVES AS FGFR INHIBITORS PRINCIPIA BIOPHARMA INC. 2018-06-07 — — US claimed
EP-3298011-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2018-03-28 — — EP claimed
US-20170348310-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-07 — — US claimed
CN-104470925-B Imidazo-triazine formonitrile HCN as kinase inhibitor 百时美施贵宝公司 2017-12-05 — — CN claimed
US-9763942-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2017-09-19 — — US claimed
WO-2016191172-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2016-12-01 — — WO claimed
EP-2897970-B1 MACROLIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-07-13 — — EP claimed
US-20150210729-A1 MACROLIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2015-07-30 — — US claimed
WO-2015103133-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-07-09 — — WO claimed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 — — US claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 — — US claimed
US-7465728-B2 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity ASTRAZENECA AB (SE) 2008-12-16 — — US claimed
US-20050131000-A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity ASTRAZENECA AB (SE) 2005-06-16 — — US claimed
EP-1487823-A1 DERIVATIVES OF 4-(IMIDAZOL-5-YL)-2-(4-SULFOANILINO)PYRIMIDINE WITH CDK INHIBITORY ACTIVITY AstraZeneca AB (SE) 2004-12-22 — — EP claimed
WO-2003076436-A1 DERIVATIVES OF 4- (IMIDAZOL-5-YL)-2-(4-SULFOANILINO) PYRIMIDINE WITH CDK INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2003-09-18 — — WO claimed
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors ASTRAZENECA UK LIMITED 2002-05-16 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210729-A1 MACROLIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF PCSK9, CYP51A1, ABCB11 KDM4E 3622/4885HSD17B10 258/4885TSHR 3190/4885
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 KDM4E 3533/4885HSD17B10 3909/4885TSHR 1295/4885
US-20180155340-A1 QUINOLONE DERIVATIVES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 KDM4E 1583/4885HSD17B10 1346/4885TSHR 3940/4885
US-10154995-B2 Serine/threonine kinase inhibitors MAP3K1, TTBK1, MAP3K11 KDM4E 3418/4885HSD17B10 2940/4885TSHR 3842/4885
US-20050131000-A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity CCNI, CDK2, CDK1 KDM4E 305/4885HSD17B10 3415/4885TSHR 3691/4885
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors FNTA, FNTB, RABGGTA KDM4E 3060/4885HSD17B10 872/4885TSHR 1795/4885
US-20170348310-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, TTBK1, MAP3K11 KDM4E 3418/4885HSD17B10 2940/4885TSHR 3842/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 KDM4E 3533/4885HSD17B10 3909/4885TSHR 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.